Zobrazeno 1 - 10
of 35
pro vyhledávání: '"C Calviño-Suárez"'
Autor:
M Chaparro, A Gutiérrez, C Calviño-Suárez, J M Huguet, M Calvo, M Aguas, R Camargo Camero, M Á de Jorge Turrión, D Hervías Cruz, P López Serrano, S Marín Pedrosa, P Martínez Montiel, M Rivero, R Vicente Lidón, L Arias García, M Arroyo, L Bujanda, M J Casanova, M Figueiras, A J Lucendo, N Manceñido Marcos, L Márquez, M D Martín-Arranz, M Boscá Watts, Y Ber, P Ramírez de la Piscina Urraca, I Pérez-Martínez, V Robles, A Ruiz-Cerulla, J M Vázquez Morón, L Madero, M Barreiro-de Acosta, M Capilla, I Vera Mendoza, D Acosta, Y Brenes, S Hermida, P Parra, M G Donday, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i491-i493
Background The safety of ustekinumab in pregnant patients with inflammatory bowel disease (IBD) and in their offspring has been barely studied. Aims Primary: To know the risk of serious adverse events (SAEs) in women exposed to ustekinumab during pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::937c68b486a568e6c69c84324094d726
https://doi.org/10.1093/ecco-jcc/jjab232.672
https://doi.org/10.1093/ecco-jcc/jjab232.672
Autor:
M Camba Gómez, L Arosa, C Calviño-Suárez, I Bastón-Rey, R Ferreiro-Iglesias, M Porto, L Nieto, J E Domínguez-Muñoz, M Barreiro-de Acosta, J Conde-Aranda
Publikováno v:
Journal of Crohn's and Colitis. 17:i818-i819
Background Vedolizumab is one of the current treatments for patients with inflammatory bowel disease (IBD). The efficacy and safety, along with its gut specificity, make this drug an appealing therapeutic option for IBD patients with moderate to seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcb8ee44c693faa4b90294c9ea0b7597
https://doi.org/10.1093/ecco-jcc/jjac190.0819
https://doi.org/10.1093/ecco-jcc/jjac190.0819
Publikováno v:
Medicine - Programa de Formación Médica Continuada Acreditado. 13:517-520
Resumen La colestasis se define como la dificultad u obstruccion, total o parcial, del flujo biliar entre el hepatocito y el duodeno. En funcion de la localizacion de la alteracion se distingue entre colestasis intrahepatica o extrahepatica. La anamn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::943b2a300d41c38f7e6b1ea603e84de3
https://doi.org/10.1016/j.med.2020.05.025
https://doi.org/10.1016/j.med.2020.05.025
Autor:
Javier P. Gisbert, E. Leo Carnerero, I Rodríguez Lago, M T Diz-Lois Palomares, Saioa Rubio, María José Casanova, B Zúñiga de Mora-Figueroa, L Arias García, José María Huguet, M Figueira, Agnès Fernández-Clotet, N. Manceñido Marcos, I Pérez Martínez, R Vicente Lidón, R Rodríguez Insa, Iván Guerra, D. Hervías Cruz, P Martínez Montiel, P Ramírez de la Piscina Urraca, C Calviño Suárez, M Aguas, M Á de Jorge Turrión, L Ramos, A Ruiz Cerulla, A Gutiérrez Casbas, P Lopez Serrano, R Armesto, P Sendra Rumbeu, S Marín Pedrosa, G Molina Arriero, R. Camargo Camero, J M Vázquez Morón, C.A. Tardillo Marín, M. Rivero, C Suarez Ferrer, E Alfambra Cabrejas, Alfredo J. Lucendo, M. Chaparro, Luis Bujanda, M García Donday
Publikováno v:
Journal of Crohn's and Colitis. 15:S086-S088
Background Prospective registries are necessary to evaluate the safety of inflammatory bowel disease (IBD) treatment during pregnancy and in children in the long term. Aims The overall aim of DUMBO registry is to know the risk of serious adverse even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::983e15f9de378a53ed0f0ec910cc6672
https://doi.org/10.1093/ecco-jcc/jjab073.091
https://doi.org/10.1093/ecco-jcc/jjab073.091
Autor:
C J Suarez Ferrer, F Mesonero, B Caballol, M P Ballester, I Baston Rey, A Castaño Garcia, J Miranda Bautista, R Saiz Chumillas, J M Benitez, L Sanchez Delgado, A Lopez-Garcia, C Rubin de Celix, A Lopez Sanroma, M D Martin-Arranz, A Fernández-Clotet, V Merino Murgui, C Calviño Suárez, P Florez, M E Lobato matilla, B Sicilia, P Soto Escribano, C Maroto Martin, I Alonso Abreu, L Melcarne, R Plaza Santos, M Marques Cami, A Caballero Mateos, C Gómez Díez, M Calafat, H Alonso Galan, P Vega Villaamil, B Castro Senosiain, A Guerro Moya, C Y Rodriguez Diaz, K Spicakova, N Manceñido Marcos, G Molina, L De Castro, M Mañosa Ciria, M Barreiro-De Acosta
Publikováno v:
Journal of Crohn's and Colitis. 16:i400-i401
Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of tumors and / or serious infections. These events are generally more frequent in elderly patients, so th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e55f479ae9ddc2a404bc8ee126606cb
https://doi.org/10.1093/ecco-jcc/jjab232.537
https://doi.org/10.1093/ecco-jcc/jjab232.537
Autor:
L Arosa García, M Camba-Gómez, C Calviño-Suárez, I Bastón-Rey, R Ferreiro-Iglesias, M Porto, L Nieto-García, J E Domínguez-Muñoz, M Barreiro-de Acosta, J Conde-Aranda
Publikováno v:
Journal of Crohn's and Colitis. 16:i147-i147
Background Vedolizumab is one of the current treatments for patients with Inflammatory Bowel Disease (IBD). The efficacy and safety, together with its gut specificity, make this drug an appealing therapeutic option for IBD patients with moderate to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58c8f4f3b9bc1caeae95f4440f881540
https://doi.org/10.1093/ecco-jcc/jjab232.151
https://doi.org/10.1093/ecco-jcc/jjab232.151
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E Sainz, M Calafat, B Botella Mateu, P Vega Villaamil, E Iyo, I Gonzalez Partida, A Caballero Mateos, Liczandro Hernandez, L Melcarne, C Calviño Suárez, Agnès Fernández-Clotet, H Alonso Galan, L Cuevas del Campo, P Perez Galindo, A López Sanromán, M Marques Cami, A López-García, M D Martin-Arranz, C Rubín de Célix, E Gonzalez Peña, Beatriz Sicilia, M C Rodriguez Grau, B Castro Senosiain, Francisco Mesonero, C Suarez Ferrer, Iria Bastón-Rey, J L Rueda García, M. Barreiro-de Acosta, Florina Ramírez, A Elosua Gonzalez, B Gomez Pastrana, R M Saiz Chumillas, C.Y. Rodríguez Díaz, R Plaza Santos, B Caballol, M. Mañosa Ciria
Publikováno v:
Journal of Crohn's and Colitis. 15:S363-S364
Background Biological drugs are being increasingly used for the treatment of inflammatory bowel diseases (IBD) in elderly patients. Despite the particular characteristics of this population subgroup, the efficacy and safety of these treatments in rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dda8646bbe4a08114cafa7d0c6b89c0e
https://doi.org/10.1093/ecco-jcc/jjab076.462
https://doi.org/10.1093/ecco-jcc/jjab076.462
Autor:
R Ferreiro-Iglesias, José Manuel Benítez, Geteccu, C. Gómez, A Bouhmidi, R M Jurado, C Calviño Suárez, M P Ballester Ferré, B. Beltrán, E Castillo, Miguel Minguez, B Hermida, Agnès Fernández-Clotet, P Besó, Raquel Muñoz, C Calvino-Suárez, E Fuentes-Valenzuela, M Vela, Carmen Duenas, P Pérez, Á Algarra, Ángel Ponferrada, C Rubín de Célix, B. Botella, Nelson Jiménez, A López, C Senosiain, N Martín, J Yebra, P Flórez-Diez, R. Plaza, E Iyo, M González-Vivó, P. Soto, E Brunet, Francisco Mesonero, J.A. Carbonell-Asins
Publikováno v:
Journal of Crohn's and Colitis. 15:S551-S552
Background Patients with colon Inflammatory Bowel Disease (IBD) have a higher risk of colorectal cancer (CRC) than general population. Current guidelines establish endoscopic surveillance recommendations; however, epidemiological studies show poor co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::498f08edd395199a333380c7de60024b
https://doi.org/10.1093/ecco-jcc/jjab076.727
https://doi.org/10.1093/ecco-jcc/jjab076.727